Dr. Passo has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than $10,000).
Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial†
Version of Record online: 29 DEC 2011
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 1, pages 297–305, January 2012
How to Cite
Kashikar-Zuck, S., Ting, T. V., Arnold, L. M., Bean, J., Powers, S. W., Graham, T. B., Passo, M. H., Schikler, K. N., Hashkes, P. J., Spalding, S., Lynch-Jordan, A. M., Banez, G., Richards, M. M. and Lovell, D. J. (2012), Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: A multisite, single-blind, randomized, controlled clinical trial. Arthritis & Rheumatism, 64: 297–305. doi: 10.1002/art.30644
ClinicalTrials.gov identifier: NCT00086047.
- Issue online: 29 DEC 2011
- Version of Record online: 29 DEC 2011
- Accepted manuscript online: 22 NOV 2011 09:08AM EST
- Manuscript Accepted: 18 AUG 2011
- Manuscript Received: 22 MAR 2011
- NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Grant Number: R01-AR-050028
Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain disorder in children and adolescents for which there are no evidence-based treatments. The objective of this multisite, single-blind, randomized clinical trial was to test whether cognitive–behavioral therapy (CBT) was superior to fibromyalgia (FM) education in reducing functional disability, pain, and symptoms of depression in juvenile FMS.
Participants were 114 adolescents (ages 11–18 years) with juvenile FMS. After receiving stable medications for 8 weeks, patients were randomized to either CBT or FM education and received 8 weekly individual sessions with a therapist and 2 booster sessions. Assessments were conducted at baseline, immediately following the 8-week treatment phase, and at 6-month followup.
The majority of patients (87.7%) completed the trial per protocol. Intent-to-treat analyses showed that patients in both groups had significant reductions in functional disability, pain, and symptoms of depression at the end of the study, and CBT was significantly superior to FM education in reducing the primary outcome of functional disability (mean baseline to end-of-treatment difference between groups 5.39 [95% confidence interval 1.57, 9.22]). Reduction in symptoms of depression was clinically significant for both groups, with mean scores in the range of normal/nondepressed by the end of the study. Reduction in pain was not clinically significant for either group (<30% decrease in pain). There were no study-related adverse events.
In this controlled trial, CBT was found to be a safe and effective treatment for reducing functional disability and symptoms of depression in adolescents with juvenile FMS.